<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:SBBP (USA) Also Trade In: Germany

Strongbridge Biopharma PLC $ 2.01 -0.06 (-2.9%)

Volume:
469,425
Avg Vol (1m):
201,834
Market Cap $:
108.91 Mil
Enterprise Value $:
24.35 Mil
P/E (TTM):
4.47
P/B:
1.19
Warning! GuruFocus has detected 3 Severe warning signs with SBBP. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for SBBP (Strongbridge Biopharma PLC) from 2015 to Oct 14 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Strongbridge Biopharma PLC stock (SBBP) PE ratio as of Oct 14 2019 is 4.47. More Details

Strongbridge Biopharma PLC PE Ratio (TTM) Chart

EMBED

Strongbridge Biopharma PLC PE Ratio (TTM) Historical Data

Total 1036
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 12
Strongbridge Biopharma PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-144.5 2019-08-125.7
2019-10-114.5 2019-08-095.6
2019-10-104.6 2019-08-085.6
2019-10-094.8 2019-08-075.5
2019-10-084.8 2019-08-065.5
2019-10-075.0 2019-08-055.5
2019-10-045.0 2019-08-025.6
2019-10-035.1 2019-08-015.7
2019-10-025.1 2019-07-315.8
2019-10-015.2 2019-07-306.0
2019-09-305.3 2019-07-295.8
2019-09-275.4 2019-07-265.9
2019-09-265.5 2019-07-255.8
2019-09-255.6 2019-07-245.8
2019-09-245.7 2019-07-235.6
2019-09-235.4 2019-07-225.9
2019-09-206.0 2019-07-196.2
2019-09-196.1 2019-07-186.3
2019-09-186.2 2019-07-176.4
2019-09-176.2 2019-07-166.1
2019-09-166.3 2019-07-156.4
2019-09-136.4 2019-07-126.5
2019-09-126.0 2019-07-116.4
2019-09-116.2 2019-07-106.4
2019-09-106.4 2019-07-096.8
2019-09-096.2 2019-07-086.8
2019-09-065.9 2019-07-057.1
2019-09-055.8 2019-07-047.2
2019-09-045.9 2019-07-037.2
2019-09-035.7 2019-07-027.2
2019-09-025.8 2019-07-017.5
2019-08-305.8 2019-06-287.0
2019-08-295.9 2019-06-2710.1
2019-08-285.2 2019-06-269.6
2019-08-275.1 2019-06-259.8
2019-08-265.4 2019-06-2410.1
2019-08-235.4 2019-06-2110.4
2019-08-225.6 2019-06-2010.7
2019-08-215.8 2019-06-1910.7
2019-08-205.9 2019-06-1810.7
2019-08-196.1 2019-06-1710.4
2019-08-165.6 2019-06-1410.0
2019-08-155.8 2019-06-139.8
2019-08-145.9 2019-06-129.8
2019-08-135.9 2019-06-119.4

Strongbridge Biopharma PLC PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Biotechnology » Biotechnology NAICS : 325414 NAICS : 2836
Traded in other countries 69BN.Germany SBBP.USA
Address 900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.